Maintaining Relative Dose Intensity in Elderly DLBCL: Clinical Strategies with Pegfilgrastim (ICBMT 2026) - Oct 8, 2026 - Abstract #LS02; Pres time: Sep 17, 2026; 12:00 PM - 12:40 PM; Location: Room C(2F); "This talk reviews the clinical significance of RDI and the role of pegfilgrastim primary prophylaxis in the context of contemporary first-line treatment, including R-CHOP and pola-R-CHP. Treatment intensity should be individualized according to fitness and comorbidities, especially in very old or frail patients. Integrating appropriate dose selection with proactive FN prevention can help balance treatment efficacy and tolerability in older adults with DLBCL."
Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin's Lymphoma
|